First Capital Inc
Change company Symbol lookup
Select an option...
FCAP First Capital Inc
FBND Fidelity Total Bond ETF
$NQEG35LMGBPN Nasdaq Egypt Real Estate Large Mid C
JNJ Johnson & Johnson
TATT TAT Technologies Ltd
MMM 3M Co
STOR STORE Capital Corp
NGG National Grid PLC
MDXG MiMedx Group Inc
GOGR Go Green Global Technologies Corp
Go

Financials : Banks | Small Cap Value
Company profile

First Capital, Inc. is the financial holding company of First Harrison Bank (the Bank), which is a wholly owned subsidiary of the Company. The Bank’s loan portfolio includes residential loans, construction loans, commercial real estate loans, commercial business loans, consumer loans, and restructured loans. It provides a range of banking services to individuals and business customers through 18 locations in Indiana and Kentucky. The Company’s loan portfolio also consists of single-family residential and commercial real estate loans in the Louisville, Kentucky metropolitan area. First Capital originates mortgage loans for sale in the secondary market, and also sells non-deposit investment products through a financial services division. FHB Risk Mitigation Services, Inc. is the subsidiary of the Company that provides property and casualty insurance coverage to the Company, the Bank and the Bank's subsidiaries, and reinsurance to over eight other third-party insurance companies.

Closing Price
$25.71
Day's Change
0.1022 (0.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
25.71
Day's Low
25.70
Volume
(Light)
Volume:
905

10-day average volume:
3,472
905

Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

7:00 am ET November 28, 2022 (Globe Newswire) Print
Viridian Therapeutics To Participate In The Evercore ISI HealthCONx ConferenceGlobeNewswireNovember 28, 2022

WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that senior management will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.

Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date: December 1, 2022
Time: 10:30 a.m. ET

The live webcast of the fireside chat will be accessible under "Events and Presentations" within "News and Events" on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available on the Company's website after the event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact:

Todd James

Viridian Therapeutics, Inc.

Senior Vice President, Corporate Affairs and Investor Relations

IR@viridiantherapeutics.com



Primary Logo

comtex tracking

COMTEX_419868280/2010/2022-11-28T07:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.